Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims

26 Oct 2023

Abstract excerpt

We identified 38 businesses advertising purported stem cell interventions and exosome products for COVID-19. These companies operated or facilitated access to 60 clinics. More than 75% of these clinics were based in the United States and Mexico. Thirty-six of the businesses marketed their stem cell and exosome products as treatments for Long COVID, six advertised them as "immune boosters," five claimed to treat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomedical Ethics and Regulation
Share to Long-Term Effects of COVID-19
Share to Neuroethics, Human Enhancement, Biomedical Innovations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37890484
DOI: 10.1016/j.stemcr.2023.09.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claimsPMID 37890484Read ↗

ISSCR’s Guidelines for Stem Cell Research and Clinical Translation: Supporting development of safe and efficacious stem cell-based interventionsSemantic proximity Read ↗

Social and private value created through commercialization of Gilead Sciences’ innovative medicines for Hepatitis C and HIV: a cross-sectional analysisSemantic proximity Read ↗

Long COVID Treatment No Silver Bullets, Only a Few Bronze BBsSemantic proximity Read ↗

Developing New Drugs for the COVID-19 Emergency: Anatomy of the U.S. Response.Semantic proximity Read ↗

Regulatory insights on advanced CAR-T cell products, AAV-based Gene therapies, and medical care/practice in cell and Gene therapies: Report from the 6th Asia partnership conference of regenerative medicine- April 20, 2023Semantic proximity Read ↗

Clinical development of gene- and cell-based therapies: overview of the European landscapeSemantic proximity Read ↗

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read ↗

The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 PatientsSemantic proximity Read ↗

Exosome cancer diagnostic reaches marketSemantic proximity Read ↗

Comparison of Clinical Evidence Submitted to the FDA and EMA for Cell and Gene TherapiesSemantic proximity Read ↗

Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatmentSemantic proximity Read ↗

Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports based on WHO Pharmacovigilance Database, VigiBaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.